Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Blueprint Medicines (BPMC) Stock Price, News & Analysis

Blueprint Medicines logo

About Blueprint Medicines Stock (NASDAQ:BPMC)

Advanced Chart

Key Stats

Today's Range
$129.46
$129.46
50-Day Range
$127.95
$129.48
52-Week Range
$73.04
$129.65
Volume
N/A
Average Volume
1.55 million shs
Market Capitalization
$8.36 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$130.00
Consensus Rating
Hold

Company Overview

Blueprint Medicines Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
10th Percentile Overall Score

BPMC MarketRank™: 

Blueprint Medicines scored higher than 10% of companies evaluated by MarketBeat, and ranked 906th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Blueprint Medicines has received a consensus rating of Hold. The company's average rating score is 2.11, and is based on 2 buy ratings, 16 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Blueprint Medicines has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Blueprint Medicines' stock forecast and price target.
  • Earnings Growth

    Earnings for Blueprint Medicines are expected to grow in the coming year, from ($1.28) to $0.65 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Blueprint Medicines is -52.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Blueprint Medicines is -52.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Blueprint Medicines has a P/B Ratio of 27.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Blueprint Medicines' valuation and earnings.
  • Short Interest

    There is no current short interest data available for BPMC.
  • Dividend Yield

    Blueprint Medicines does not currently pay a dividend.

  • Dividend Growth

    Blueprint Medicines does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for BPMC.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Blueprint Medicines this week, compared to 8 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Blueprint Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $640,491.00 in company stock.

  • Percentage Held by Insiders

    Only 4.21% of the stock of Blueprint Medicines is held by insiders.

  • Read more about Blueprint Medicines' insider trading history.
Receive BPMC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter.

BPMC Stock News Headlines

The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.tc pixel
BPMC Blueprint Medicines Corporation - Seeking Alpha
Blueprint Medicines Corporation (BPMC) - Yahoo Finance
See More Headlines

BPMC Stock Analysis - Frequently Asked Questions

Blueprint Medicines Corporation (NASDAQ:BPMC) posted its quarterly earnings data on Thursday, May, 1st. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by $0.32. The company's quarterly revenue was up 55.5% on a year-over-year basis.
Read the conference call transcript
.

Blueprint Medicines (BPMC) raised $115 million in an initial public offering on Thursday, April 30th 2015. The company issued 7,200,000 shares at $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Top institutional investors of Blueprint Medicines include State Street Corp (3.45%), OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC (2.65%), Geode Capital Management LLC (2.39%) and Norges Bank (1.66%). Insiders that own company stock include Kate Haviland, Jeffrey W Albers, Fouad Namouni, Christina Rossi, Tracey L Mccain, Percy H Carter, Michael Landsittel, Debra Durso-Bumpus, Christopher K Murray, Philina Lee, L Becker Hewes and Ariel Hurley.
View institutional ownership trends
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Blueprint Medicines investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), Humana (HUM), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
5/01/2025
Today
8/20/2025
Next Earnings (Estimated)
10/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BPMC
CIK
1597264
Fax
N/A
Employees
640
Year Founded
2011

Price Target and Rating

High Price Target
$135.00
Low Price Target
$119.00
Potential Upside/Downside
+0.4%
Consensus Rating
Hold
Rating Score (0-4)
2.11
Research Coverage
18 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.47)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$67.09 million
Net Margins
-27.70%
Pretax Margin
-27.38%
Return on Equity
-64.60%
Return on Assets
-17.22%

Debt

Debt-to-Equity Ratio
1.01
Current Ratio
2.80
Quick Ratio
2.75

Sales & Book Value

Annual Sales
$562.12 million
Price / Sales
14.87
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.70 per share
Price / Book
27.54

Miscellaneous

Outstanding Shares
64,582,000
Free Float
61,863,000
Market Cap
$8.36 billion
Optionable
Optionable
Beta
0.89

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:BPMC) was last updated on 8/20/2025 by MarketBeat.com Staff
From Our Partners